elderly patients than younger patients [84/609 (13.8%) versus 62/1106 (5.6%)] and among elderly patients receiving enzalutamide than those receiving placebo [61/317 (19.2%) versus 23/292 (7.9%)].
Conclusions: Elderly men benefited from treatment with enzalutamide in terms of OS and rPFS. Enzalutamide was well tolerated in the elderly subgroup and those aged <75 years. Age and enzalutamide treatment were associated with a higher incidence of falls.
Clinical trial identifier: NCT01212991, ClinicalTrials.gov.
Key words: metastatic castration-resistant prostate cancer, enzalutamide, PREVAIL trial, elderly patients introduction Prostate cancer claimed >300 000 lives worldwide in 2012, representing the fifth leading cause of death from cancer in men (∼6.6% of total male cancer-related deaths) [1] . According to a United States-based analysis using the Surveillance, Epidemiology, and End Results database, 26% of men diagnosed with prostate cancer are ≥75 years of age (henceforth termed 'elderly'), yet they account for a disproportionate percentage of patients with metastatic disease at diagnosis (48%) and prostate cancer-specific deaths (53%) [2] . Since United States men who reach their mid-seventies have a 10-year life expectancy, use of age only as a determinant of treatment options is clearly discriminatory [3] .
Management of prostate cancer in the elderly remains suboptimal across the disease continuum [4, 5] . In the case of metastatic disease, docetaxel chemotherapy is reasonably safe and associated with improved overall survival (OS) in elderly patients with castration-resistant prostate cancer (CRPC) and a good performance status [6] , yet many elderly patients never receive docetaxel [5] . These trends are particularly disturbing given that prostate cancer diagnosed in the elderly is associated with greater mortality than prostate cancer diagnosed in younger men [7] .
In the past 5 years, novel agents with distinct mechanisms of action have demonstrated improved survival in men with metastatic CRPC (mCRPC) [8] . The oral androgen receptor inhibitor enzalutamide improved OS, radiographic progression-free survival (rPFS), risk of skeletal-related events (SREs), and healthrelated quality of life relative to placebo in men with mCRPC both before docetaxel (in PREVAIL) and after docetaxel (in AFFIRM) [9, 10, 11, 12] . A post hoc analysis of AFFIRM revealed that enzalutamide significantly improved outcomes in both younger (<75 years) and elderly patients relative to placebo, with comparable safety and tolerability between the age groups [13] .
To assess the benefit of enzalutamide treatment in elderly patients who were chemotherapy-naive, we conducted pre-specified efficacy and safety analyses of the PREVAIL clinical trial data stratified by patient age (<75 versus ≥75 years).
patients and methods

study design and participants
The full methodology of the international, randomised, double-blind, placebo-controlled, phase III PREVAIL study (NCT01212991) has been reported [9] . Consenting patients enrolled in PREVAIL were chemotherapynaive men aged ≥18 years with histologically or cytologically confirmed metastatic adenocarcinoma of the prostate that was castration resistant. Patients were randomised 1:1 to enzalutamide 160 mg by mouth daily or placebo. Treatment was discontinued for: (i) intolerance or (ii) either confirmed radiographic progression or an SRE and initiation of another therapy for prostate cancer.
assessments
The coprimary end points in PREVAIL were OS and rPFS, the latter end point defined as time from randomisation to the first objective evidence of radiographic disease progression assessed by a blinded independent central review facility or death due to any cause within 168 days after treatment discontinuation, whichever occurred first. Secondary end points were time to initiation of chemotherapy, time to first SRE, time to prostate-specific antigen (PSA) progression, and proportion of patients with a decline in PSA ≥50%. Exploratory end points included time to first degradation and percentage improvement in the Functional Assessment of Cancer TherapyProstate (FACT-P) scale total score and its subscales [12, 14] , percentage of patients with pain progression on the Brief Pain Inventory [15] , and the Response Evaluation Criteria In Solid Tumors objective response rate [16, 17] . Safety results were reported by analysis of adverse events (AEs) in the treatment arms of both subgroups and graded according to the Common Terminology Criteria for Adverse Events version 4. We were particularly interested in assessing the incidence of falls in PREVAIL since an imbalance in falls between enzalutamide-and placebo-treated patients was identified in AFFIRM [10] .
statistical analysis
Analysis of elderly patients (i.e. ≥75 years of age) at the time of study entry was pre-specified for OS, rPFS, and AEs. Dichotomising age at this threshold is routine when investigating outcomes in patients with mCRPC receiving pharmacotherapy [6, 13, 18, 19] . Age-stratified analyses of secondary and exploratory efficacy end points were carried out post hoc. Baseline and efficacy data were analysed using the intent-to-treat population (i.e. all randomised patients), whereas safety data were analysed in all randomised patients who received at least one dose of study drug. All results are superiority analyses with two-sided P values.
results
patients and treatment
In the elderly subgroup (N = 609), 317 patients received enzalutamide and 292 received placebo, and in patients <75 years of age (N = 1108), 555 received enzalutamide and 553 received placebo. (Figures 1 and 2) . In elderly patients, enzalutamide treatment was associated with a reduction in the risk of radiographic progression or death [median NYR in the enzalutamide arm (95% CI 12.3-NYR) versus 3.7 months in the placebo arm (95% CI 3.6-5.3); HR = 0.17; 95% CI 0.12-0.24; P < 0.0001] (Figures 1  and 2 ). Similar improvements in median duration of OS and rPFS were detected in the enzalutamide arm versus the placebo arm in patients aged <75 years.
In the elderly subgroup, enzalutamide was associated with improved outcomes in all secondary and exploratory end points relative to placebo ( Figure 1 ; supplementary Figure S1 , available at Annals of Oncology online). Deterioration in all but one domain of the FACT-P questionnaire was delayed in the enzalutamide arm relative to the placebo arm in the elderly subgroup (supplementary Figure S2 , available at Annals of Oncology online). The proportion of elderly patients with a clinically meaningful improvement in FACT-P total score and each of its subscales (with the exception of physical well-being) was higher in the enzalutamide arm than in the placebo arm (supplementary Table S2 , available at Annals of Oncology online). In the elderly subgroup, the PSA and best objective response rates were higher in the enzalutamide arm than placebo arm (Table 2 ). In this largely asymptomatic population, no differences between enzalutamide and placebo were detected in either age group regarding the proportion of patients with pain severity progression at week 25 ( Table 2) .
safety
The safety profile of enzalutamide was similar in the two age groups except for a higher incidence of any grade ≥3 AEs (48.9% versus 39.5%), falls (any grade, 19.2% versus 7.2%; grade ≥3, 2.2% versus 0.9%), fractures (15.8% versus 9.9%), decreased appetite (22.1% versus 15.9%), and asthenia (17.0% versus 10.6%) in the elderly subgroup (Table 3 ). Similar observations were evident in the placebo subgroups.
Although the incidences of these AEs (as well as fatigue) were also higher in the enzalutamide arm than placebo arm of the elderly subgroup, fall rate was the only AE that remained higher in the enzalutamide arm after adjusting for length of treatment exposure (18.4 versus 13.4 events per 100 patient-years; Table 3 ). There was no difference between younger patients receiving enzalutamide and those receiving placebo on this measure. In both age groups, a greater proportion of enzalutamide-treated patients who fell [37/101 (36.6%)] than placebo-treated patients who fell [11/45 (24. 4%)] had a subsequent non-pathological fracture in the next 14 days. A similar trend of AE rates across treatment arms was observed in patients <75 years of age, except that there was a higher rate of non-pathological (e.g. osteoporotic) fractures in the enzalutamide arm (6.2 versus 2.8 events per 100 patient-years).
Causes of death were similar in each treatment arm of the elderly subgroup (supplementary Table S3 , available at Annals of Oncology online), most of which were due to disease progression [enzalutamide, 76/100 (76%); placebo, 88/129 (68%)].
subsequent anti-neoplastic therapy
After study treatment discontinuation, a lower proportion of elderly patients than those aged <75 years received chemotherapy with either docetaxel (32.3% versus 51.3%) or cabazitaxel (3.3% versus 12.7%) (supplementary Table S4 , available at Annals of Oncology online). The elderly were also less likely to receive abiraterone acetate plus prednisone (27.6% versus 35.7%).
discussion
In this subgroup analysis of PREVAIL, enzalutamide was associated with prolonging OS and rPFS, while delaying biochemical and symptomatic deterioration to a similar extent in elderly patients and patients aged <75 years. Furthermore, enzalutamide was as safe and well tolerated in elderly patients as it was in younger patients, although the drug may slightly increase the risk for falls in elderly patients. In PREVAIL, the cause of death in elderly patients was overwhelmingly related to disease progression, which supports the finding that older men with mCRPC predominantly die of prostate cancer and not of ageing-related comorbidities [2] .
PREVAIL enrolled the largest number of men with mCRPC aged ≥75 years in a randomised clinical trial of any agent for mCRPC [9] , and it provides an opportunity to examine baseline characteristics as well as outcomes in this elderly, albeit selected, population. Not surprisingly, baseline comorbidities disproportionately affected the elderly subgroup. Elderly patients also had median baseline PSA levels twice those of younger patients. Despite having an increased median time from initial diagnosis to enrolment in the study of nearly 3 years relative to the younger patients, the elderly subgroup received a similar number of prior anti-androgen treatments and had a similar burden of metastatic bone disease at baseline. Although elderly patients had more negative prognostic characteristics, comorbidities, and Figure 1 . Risk of an event with enzalutamide relative to placebo in patients aged <75 years or ≥75 years who participated in the phase III PREVAIL trial (ITT population). A minimally important difference on the FACT-P scale total score was defined as a ≥10-point change [12, 14] . CI, confidence interval; FACT-P, Functional Assessment of Cancer Therapy-Prostate total score; HR, hazard ratio; ITT, intent-to-treat; NYR, not yet reached; PFS, progression-free survival; PSA, prostate-specific antigen; SRE, skeletal-related event.
Volume There was a large asymmetry in the duration of time when AEs were collected between the active treatment arm and placebo, due to the efficacy of enzalutamide. Adjustment for time on treatment is therefore of interest in interpreting AE results. The higher time-adjusted rate of decreased appetite and fatigue in the placebo arm versus enzalutamide arm of both age groups raises the possibility that these AEs are related more to disease progression than drug treatment per se. There was a higher incidence of falls in the elderly subgroup, independent of treatment arm, as well as a higher incidence of falls in the enzalutamide than placebo arm of the elderly subgroup. The potential for enzalutamide to increase risk for falls first came to light in the AFFIRM study [10] . Subsequent analysis of individual patient data from AFFIRM revealed that 11 of 303 elderly patients (3.6%) experienced a fall [9/303 (3.0%) in the enzalutamide arm and 2/303 (0.6%) in the placebo arm]. Of the patients aged <75 years, 26 of 896 (2.9%) fell, including 23 in the enzalutamide arm (2.6%) and 3 in the placebo arm (0.3%) (Medivation, Inc., data on file). When adjusted for exposure time, the fall rate in AFFIRM for patients aged ≥75 years receiving enzalutamide was similar to the rate in those receiving placebo (6.9 versus 4.9 events per 100 patient-years), but it was greater in those aged <75 years receiving enzalutamide (5.6 versus 2.4 events per 100 patient-years) (Medivation, Inc., data on file).
A full evaluation of fall risk with enzalutamide is beyond the scope of the current subgroup analysis. Falls do represent a substantial source of morbidity among the elderly in general [21] and among elderly patients with cancer in particular [22] . Androgen deprivation therapy (ADT) alone is known to result in significant impairment in activities of daily living and increased risk of falls in men with prostate cancer [23] . Our data imply that enzalutamide may further increase that risk since all participants were also on ADT. The specific reason(s) for the falls are unclear but might relate to the impact of fatigue, induction of skeletal muscle atrophy by potent androgen receptor Stratified treatment comparisons were generated for each age group comparing enzalutamide versus placebo. Differences in response rates were based on standard normal approximations. The ranges reported are 95% CIs. b Defined as the proportion of patients with decline of ≥50% in PSA level. Only patients who had both baseline and post-baseline assessments were analysed. Confirmation required a subsequent assessment that was consecutive and conducted ≥3 weeks later, in line with recommendations of the Prostate Cancer Clinical Trials Working Group [16] . The 95% CI for PSA response rate was based on exact binomial 95% CI (Clopper-Pearson).
d RECIST criteria were determined in patients with measurable disease at baseline [16, 17] .
e Only patients with measurable soft-tissue disease (i.e. ≥1 target lesion identified per RECIST version 1.1) at screening were included in the analysis. f Difference in best objective response defined as a complete or partial response. g Defined as a ≥30% increase in average BPI pain intensity item scores (items 3, 4, 5, and 6) from baseline to week 25 [20] . Only patients who had both baseline and week 25 assessments were included in the analysis. BPI, Brief Pain Inventory; PSA, prostate-specific antigen; CI, confidence interval; RECIST, Response Evaluation Criteria in Solid Tumors. inhibition, and concomitant medications pre-disposing patients to a fall [24, 25] . The incidence rate of non-pathological fracture in patients aged <75 years who received enzalutamide was higher than that in those who received placebo, which may be clinically important as there were no clear differences between the treatment groups regarding concomitant use of systemic corticosteroids, denosumab, and bisphosphonates.
Our data corroborate previous reports that second-generation hormone therapy is safe and effective in men aged ≥75 years, reinforcing the stance that physicians should not discriminate on the basis of age alone when selecting treatment for mCRPC [13, 18, 19] . They are also consistent with results showing that enzalutamide extended survival, improved secondary outcomes, and was well tolerated among elderly patients who had received docetaxel before participating in AFFIRM [10] . Two post hoc subgroup analyses revealed that hormone manipulation with abiraterone acetate plus prednisone improves OS and is well tolerated in elderly patients in the chemotherapy-naive (COU-AA-302) and post-docetaxel (COU-AA-301) settings [18, 19] . The lack of a need for adjunctive corticosteroid therapy is a distinguishing feature of enzalutamide treatment. Aside from the endocrinerelated AEs due to corticosteroid use concomitant with abiraterone acetate, enzalutamide and abiraterone acetate have unique safety profiles that should be borne in mind when selecting patients for either therapy. An increased fall risk was not reported among the elderly in COU-AA-302 treated with abiraterone acetate plus prednisone, but this regimen was associated with a higher incidence of treatment-emergent AEs leading to death, fatigue and grade ≥3 fatigue, grade ≥3 hepatotoxicity, and grade ≥3 cardiac disorders than prednisone, although these safety data were not adjusted for time on therapy [19] . The correct sequencing of enzalutamide and abiraterone acetate plus prednisone, and their potential as a combination regimen, in patients with mCRPC
is not yet known.
In conclusion, the data show that elderly patients included in PREVAIL had a heavier disease burden, poorer functional status, and more underlying cardiovascular disease, but nevertheless derived similar benefit from enzalutamide as did patients aged <75 years. Overall, there are clear benefits with enzalutamide in improving OS, delaying disease progression in the elderly, and maintaining quality of life, although attention to falls is required as part of routine medical management in this at-risk population. The efficacy and tolerability of enzalutamide demonstrated in the elderly subgroup of PREVAIL further supports resisting therapeutic nihilism in approaching treatment decisions for elderly patients with advanced prostate cancer and may allow a higher proportion of them to receive life-extending treatment. funding Medivation, Inc., and Astellas Pharma Global Development, Inc., funded the PREVAIL trial, provided the study drug and collaborated with the investigators on protocol design, data analysis and interpretation, and preparation of this report, including the support of medical writing and editorial services (no grant number).
